Intravitreal Bevacizumab for Choroidal Neovascularization in Ocular Histoplasmosis

Ramin Schadlu, Kevin J. Blinder, Gaurav K. Shah, Nancy M. Holekamp, Matthew A. Thomas, M. Gilbert Grand, Nicholas E. Engelbrecht, Rajendra S. Apte, Daniel P. Joseph, Anita G. Prasad, Bradley T. Smith, Arsham Sheybani

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Purpose: To define the role of intravitreal bevacizumab in individuals with choroidal neovascularization (CNV) resulting from Ocular Histoplasmosis syndrome (OHS). Design: Retrospective chart review of a surgical therapy. Methods: We reviewed the course of 28 eyes of 28 patients who underwent intravitreal injection of bevacizumab for treatment of CNV secondary to OHS. Outcome was measured by pretreatment and posttreatment visual acuity (VA). Results: The average pretreatment logarithm of the minimum angle of resolution (logMAR) VA was 0.65 (Snellen equivalent of 20/88). Mean follow-up was 22.43 weeks with an average of 1.8 intravitreal injections. Average final logMAR VA was 0.43 (Snellen equivalent of 20/54). Twenty eyes (71%) experienced an increase in central VA, whereas four eyes (14%) were unchanged and four eyes (14%) experienced a decrease in vision. Conclusions: Intravitreal bevacizumab may improve or stabilize VA in a significant majority of patients with neovascular complications of OHS (24 eyes [85.7%] in our study population).

Original languageEnglish
Pages (from-to)875-878.e2
JournalAmerican journal of ophthalmology
Issue number5
StatePublished - May 2008


Dive into the research topics of 'Intravitreal Bevacizumab for Choroidal Neovascularization in Ocular Histoplasmosis'. Together they form a unique fingerprint.

Cite this